Novartis Thinks it Has a Monopoly on MS..

Novartis is a big company and probably has a monopoly on a lot things. There isn't an exact cure but Novarits has a therapy that sends MS into remission 21% of the time. According to Carly Helmand, "Siponimod cut the risk of disease progression by 21% in patients with secondary progressive multiple sclerosis (SPMS)--a “highly disabling” form of the disease for which there are currently no approved treatments." If we were patients I would not like those odds. But what choice do they have if Novartis is the only option. MS is a serious condition that drastically effects people. Not for a couple days or weeks, but for potentially their whole life. Studies on Low Dose Naltrexone (LDN) have found some astonishing results that are very beneficial to patients with MS. This little know drug is approved in the NAFDAC to treat HIV/AIDS. HIV and MS alike they both attack the immune system waking the its own defenses. LDN is an immune therapy treatment that rebalances your immune system. No matter which part of you immune system is deficient or even too much f it balances back to what it should be. This allows the body to naturally fight diseases like MS and HIV.

"The use of low doses of naltrexone for the treatment of multiple sclerosis (MS) enjoys a worldwide following amongst MS patients. There is overwhelming anecdotal evidence, that in low doses naltrexone not only prevents relapses in MS but also reduces the progression of the disease. It is proposed that naltrexone acts by reducing apoptosis of oligodendrocytes. It does this by reducing inducible nitric oxide synthase activity. This results in a decrease in the formation of peroxynitrites, which in turn prevent the inhibition of the glutamate transporters. Thus, the excitatory neurotoxicity of glutamate on neuronal cells and oligodendrocytes via activation of the alpha-amino-3-hydroxy- 5-methyl-isoxazole-4-propionic acid class of glutamate receptor is prevented. It is crucial that the medical community respond to patient needs and investigate this drug in a clinical trial."